Friday, 16 October 2026European Markets

SMARTPHOTO GROUP And ABEO Have A High Dividend Yield And Return On Equity In The Leisure Industry.

Loading stream...

(vianews) - smartphoto group (smar.br) is among this list of stock assets with the highest dividend rate and return on equity on the leisure industry.

financial asset price forward dividend yield return on equity
smartphoto group (smar.br) €27.50 3.76% 11.25%
abeo (abeo.pa) €17.50 2.07% 8.59%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. smartphoto group (smar.br)

3.76% forward dividend yield and 11.25% return on equity

smartphoto group nv engages in the b2c e-commerce business in europe. the company offers personalized products, including gifts, cards, photo books, photo calendars, prints, and wall decoration under the smartphoto brand name. it also engages in the e-commerce distribution of personalized gift packages with chocolate, alcohol, fruit, and flowers under the nayan brand name through websites comprising gift.be and giftsforeurope.com. the company was formerly known as spector photo group nv and changed its name to smartphoto group nv in may 2013. smartphoto group nv was founded in 1964 and is based in wetteren, belgium.

earnings per share

as for profitability, smartphoto group has a trailing twelve months eps of €1.39.

pe ratio

smartphoto group has a trailing twelve months price to earnings ratio of 19.78. meaning, the purchaser of the share is investing €19.78 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.25%.

sales growth

smartphoto group's sales growth for the current quarter is 33.6%.

revenue growth

year-on-year quarterly revenue growth grew by 12.6%, now sitting on 77.57m for the twelve trailing months.

more news about smartphoto group.

2. abeo (abeo.pa)

2.07% forward dividend yield and 8.59% return on equity

abéo sa designs, manufactures, and distributes sports and leisure equipment in france and internationally. it offers gymnastics apparatus and landing mats, team sports equipment, physical education, climbing walls, and changing room fittings. it offers its products under the gymnova, janssen-fritsen, spieth gymnastics, schelde sports, spieth america, sportsafe, erhard sport, adec sport, o'jump, cannice, bosan, pcv, vogoscope, bigairbag, entre-prises, clip'n climb, top30, fun spot, climbat, france equipement, meta, prospec, navic, sanitec, suffixe, and sanelite brands. the company was founded in 1955 and is headquartered in rioz, france.

earnings per share

as for profitability, abeo has a trailing twelve months eps of €0.89.

pe ratio

abeo has a trailing twelve months price to earnings ratio of 19.66. meaning, the purchaser of the share is investing €19.66 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.59%.

volume

today's last reported volume for abeo is 20 which is 97.77% below its average volume of 899.

revenue growth

year-on-year quarterly revenue growth grew by 23.2%, now sitting on 227.46m for the twelve trailing months.

more news about abeo.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com